The time has come for the pharmaceutical industry to seize the opportunities offered by artificial intelligence. At Sanofi, this transformation takes the form of a bold strategy led by Florent Edouard, Global Head of the Digital Accelerator. After an international career at AstraZeneca and Grünenthal, he carries an ambitious vision: to reposition artificial intelligence at the heart of the marketing and commercial activities of the French giant.

The discussion revolved around the transformative role of AI in clinical trials, supported by insights from Pfizer and Artefact, and highlighted in their collaborative white paper. It showcased concrete use cases, ecosystem mapping, and challenges to scaling AI innovations.

This roundtable explored the transformative role of GenAI in drug discovery, highlighting its potential to optimize processes, accelerate timelines, and foster collaboration in the pharmaceutical industry.

The roundtable focused on the transformative potential of AI and (GenAI) in omni-channel engagement for healthcare professionals (HCPs). The discussion explored how AI reshapes interactions, drives personalized experiences, and enhances processes across clinical trials, marketing, and patient engagement.

Pfizer is leveraging AI to revolutionize drug development. AI is viewed as a game-changer, impacting every stage of the pharmaceutical process, from preclinical research to patient access and manufacturing, with both operational and transformative applications.

Servier has approached AI adoption in two phases. Initially, an opportunistic approach focused on proving AI's potential through specific use cases, especially in collaboration with R&D teams.

This roundtable at the AI for Health Summit 2024 focused on the use of health data and artificial intelligence to address diagnostic delays and impasses for rare diseases. With contributions from key players in research, healthcare, and industry, this discussion emphasized the need for collective mobilization to enhance the lives of over 3 million patients in France affected by rare diseases.

Read the synthesis of Artefact's report and discover insights from healthcare and pharma companies, like Servier, Pfizer, Johnson & Johnson, Google, Elaia, Inato, Klineo, Deemea, and Naaia.